Abstract: A prosthetic device is controlled based on measured electrical signals corresponding to muscle activity in a lower-extremity anatomical analog to a dysfunctional or absent portion of an upper extremity of an individual. In particular, an activity monitoring device measures electrical signals corresponding to muscle activity in the lower-extremity anatomical analog. Then, a communication device communicates information specifying the electrical signals to a pattern-recognition device. The pattern-recognition device identifies a natural mode of movement of the lower-extremity anatomical analog based on the information. For example, the natural mode of movement may be identified using a pattern-recognition technique.

Abstract: Automated image analysis systems and methods are disclosed to quantify change in fibrosis and interstitial lung disease. The system generates scoring changes in Quantitative Interstitial Lung Disease (QILD) by filtering the uploaded images to minimize cross-site variability within images, sampling from a grid of pixels or voxels within the CT images, classifying individual pixels or voxels within downloaded images based on one or more selected texture features, generating a QILD score for each image based on selected features within the image, and calculating a transition between QILD scores within the plurality of CT images.

Abstract: The invention provides a method for detection of lung cancer, or predisposition to lung cancer, in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of lung cancer, or predisposition to lung cancer. The method can be adapted for quantitatively monitoring the efficacy of treatment of lung cancer in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitrotyrosine oxidative activity (protein nitrosylation in leukocytes). This unexpected discovery of markers of systemic genotoxicity that can be tested using circulating leukocytes enables detection of lung cancer, or predisposition to lung cancer, with a relatively simple and minimally invasive assay using peripheral blood.

Abstract: The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.

Abstract: To manufacture a nanophotonic device, a metal oxide precursor is mixed with an organic acid, an organic polymer and a photoinitiator in a solvent to form a dispersion comprising a hybrid organic-inorganic phase. A film is formed on a substrate form the dispersion, the film including the hybrid organic-inorganic phase. The film is annealed to transform the hybrid organic-inorganic phase into an inorganic phase.

Abstract: One embodiment of the present disclosure provides an ion mobility spectrometry (IMS) device for performing chemical analysis. The IMS device includes a first set of electrodes arranged linearly in a first direction and separated by a first set of gaps. The IMS device includes a second set of electrodes positioned directly opposing the first set of electrodes to match the first set of electrodes on a one-to-one basis, wherein the second set of electrodes are separated by a second set of gaps. The IMS device includes a drift region between the first set of electrodes and the second set of electrodes, wherein charged particles enter at a first end of the drift region and traverse the drift region along the first direction. The IMS device additionally includes a detector positioned at a second end of the drift region and configured to receive charged particles exiting the drift region.

Abstract: The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.

Abstract: A projector configured to provide higher resolution output without increasing pixel resolution in a light modulator is disclosed. The projector may introduce an optical element between a light modulator and an imaging lens. The optical element may provide pixel sharing of a target image. The pixel sharing may be produced by, for example, making smaller copies of pixels. Selected copies of pixels may be passed to the imaging lens to display an output image with selected areas of higher density pixels.

Abstract: Magnetically responsive photonic nanochains that have been produced by inducing chaining of uniform magnetic particles during their silica coating process and then allowing additional deposited silica to wrap entire structures. The optical diffraction of these nanochains can be switched on and off by applying magnetic fields.

Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject.

Abstract: The invention concerns a particle having a code from a library of codes embedded in its physical structure by refractive index changes between different regions of the particle. In preferred embodiments, a thin film possesses porosity that varies in a manner to produce a code detectable in the reflectivity spectrum. An assay detection method uses such a particle and detects a spectral shift in the presence of an analyte. Additional embodiments are disclosed including additional features.

Abstract: A non-volatile electro-mechanical diode memory cell is described for implementation of compact (4F2) cross-point memory arrays. The electro-mechanical diode memory cells operate with relatively low set/reset voltages and excellent retention characteristics, and are multi-time programmable. Due to its simplicity, this electro-mechanical diode memory cell is attractive for implementation of three-dimensional memory arrays for higher storage density.

Abstract: The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

Abstract: A multicolor electronic display is based on an array of luminescent semiconductor nanocrystals. Nanocrystals which emit tight of different colors are grouped into pixels. The nanocrystals are optically pumped to produce a multicolor display. Different sized nanocrystals are used to produce the different colors. A variety of pixel addressing systems can be used.

Abstract: Various compounds, compositions, and methods for binding to ?-amyloid plaque and norepinephrine transporters are presented. Especially preferred compounds include those with a PET-detectable label.

Abstract: Compositions of porous thin films and methods of making are provided. The methods involve self-assembly of a cyclic peptide in the presence of a block copolymer.

Abstract: The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.

Abstract: Provided are methods of identifying biomarkers that cause or promote progression of disease. The successful application of the methods is demonstrated by the identification of biomarkers associated with and/or causative of the onset and/or progression and/or severity and/or recurrence of glaucoma and POAG. Many of these biomarkers were not previously associated with glaucoma or POAG. Predictive methods are also described, as well as applications in prognosis, diagnosis, and therapy. Testing for onset, progression, severity, and/or recurrence can be carried out. A key advantage in at least some embodiments is that a patient can receive earlier treatment for the disease such as POAG by use of the methods, screenings, and predictions described herein. Another key advantage in at least some embodiments is that a patient can receive more personalized or particular treatment for the disease such as POAG by use of the methods, screenings, and predictions described herein.

Abstract: Simvastatin is a drug used in treatment of hypercholesterolemia because of its inhibitory activities towards cholesterol biosynthesis. The technology described herein is a novel method of biosynthesizing Simvastatin directly from an engineered microbial host (such as Saccharomyces cerevisiae) using an engineered biosynthetic pathway. The identification and engineering of Aspergillus terreus biosynthetic pathways opens up new metabolic engineering opportunities for statin production from organisms such as yeast. Using this technology, Simvastatin can be obtained by feeding a simple synthetic building block to fermented culture. Such methods provide a cost-effective way of obtaining Simvastatin including, for example, one-pot fermentation processes.